Pharmacogenetic comparison of CYP2D6 predictive and measured phenotypes in a South African cohort

  • The Pharmacogenomics Journal volume 17, page 393 (2017)
  • doi:10.1038/tpj.2017.20
  • Download Citation

Correction to: The Pharmacogenomics Journal (2016) 16, 566–572; doi:10.1038/tpj.2015.76; published online 27 October 2015

In the originally published version of this paper, the author affiliations were incorrect. The correct affiliations appear below. The publisher regrets the error.

TM Dodgen1,2, C De J Labuschagne3, A van Schalkwyk3, FE Steffens4, A Gaedigk5, AD Cromarty1, M Alessandrini2 and MS Pepper2,6

1Department of Pharmacology, University of Pretoria, Pretoria, South Africa;

2Department of Immunology and Institute for Cellular and Molecular Medicine, University of Pretoria, Pretoria, South Africa;

3Inqaba Biotechnical Industries, Pretoria, South Africa;

4Department of Consumer Science, University of Pretoria, Pretoria, South Africa;

5Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children’s Mercy Kansas City, and School of Medicine, University of Missouri-Kansas City, Kansas City, MO, USA;

6Department of Genetic Medicine and Development, University of Geneva, Geneva, Switzerland.


  1. Search for T M Dodgen in:

  2. Search for C De J Labuschagne in:

  3. Search for A van Schalkwyk in:

  4. Search for F E Steffens in:

  5. Search for A Gaedigk in:

  6. Search for A D Cromarty in:

  7. Search for M Alessandrini in:

  8. Search for M S Pepper in: